» Articles » PMID: 22321610

Monitoring of Tumour Progression Using Bioluminescence Imaging and Computed Tomography Scanning in a Nude Mouse Orthotopic Model of Human Small Cell Lung Cancer

Overview
Journal Lung Cancer
Specialty Oncology
Date 2012 Feb 11
PMID 22321610
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Human small cell lung carcinoma (SCLC) is the most aggressive type of lung cancer but no clinically relevant animal model has been developed to date. Such a model would be valuable to study the molecular aspects of tumour progression and to test the effectiveness of new treatment agents. We generated a reproducible and reliable nude mouse orthotopic model of human SCLC with NCI-H209 tumour cells genetically modified to express firefly luciferase. Cells were analysed for long-term stability of bioluminescence and a clone was passaged twice subcutaneously to enhance tumorigenicity. Cells resuspended in Matrigel and/or EDTA RPMI medium containing a (99m)Tc-labelled tin colloid used as tracer were implanted intrabronchially with a catheter inserted into the trachea and positioned in the main bronchus using X-ray-guided imaging. Deposition of cells into the lung was then assessed by scintigraphy. The growth of the primary tumour was sensitively and non-invasively followed by bioluminescence imaging that allowed real-time monitoring of tumour progression in the same animals over a 2-12-week period. Additional 3D bioluminescence imaging and computed tomography scanning were used to document tumour location and measurements that were confirmed by histological analyses. In conclusion, this original nude mouse orthotopic model resembles various stages of human small cell lung cancer, and therefore could be used to evaluate new treatment strategies.

Citing Articles

Precise and Facile Endotracheal Lung-tumor-implantation Mouse Model Visualized by GFP Expression.

Aoki Y, Kobayashi K, Varshney N, Kubota Y, Masaki N, Obara K In Vivo. 2023; 37(4):1477-1481.

PMID: 37369517 PMC: 10347943. DOI: 10.21873/invivo.13231.


Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines.

Nguyen P, Allard-Vannier E, Aubrey N, Labrugere-Sarroste C, Chourpa I, Sobilo J Pharmaceutics. 2022; 14(12).

PMID: 36559172 PMC: 9784797. DOI: 10.3390/pharmaceutics14122679.


The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.

Blanquart C, Jaurand M, Jean D Front Oncol. 2020; 10:388.

PMID: 32269966 PMC: 7109283. DOI: 10.3389/fonc.2020.00388.


Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios.

Aktar R, Dietrich A, Tillner F, Kotb S, Lock S, Willers H Br J Radiol. 2018; 92(1095):20180539.

PMID: 30215546 PMC: 6541193. DOI: 10.1259/bjr.20180539.


Establishment and evaluation of the VX2 orthotopic lung cancer rabbit model: a ultra-minimal invasive percutaneous puncture inoculation method.

Wang L, Che K, Liu Z, Huang X, Xiang S, Zhu F Korean J Physiol Pharmacol. 2018; 22(3):291-300.

PMID: 29719451 PMC: 5928342. DOI: 10.4196/kjpp.2018.22.3.291.